Centessa Pharmaceuticals is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients.

Centessa Pharmaceuticals are developing potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for the treatment of sleep-wake disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), and excessive daytime sleepiness (EDS) in neurological, neurodegenerative, and neuropsychiatric conditions. We also anticipate that our orexin agonists may have utility in treating impaired attention, cognitive deficits, fatigue and other symptoms. Their earlier stage pipeline also includes our proprietary LockBody® technology platform.